CClinicalTrials.gg
CompletedNCT02556957mLAKEUpdated Aug 31, 2020

CHWs, mHealth, and Combination HIV Prevention

An interventional study of HealthScouts and Standard of Care in HIV, sponsored by Johns Hopkins University. Completed at 1 site in Uganda. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-31.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
3,773
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Study summary

Kasensero, a fishing community on Lake Victoria in Uganda, is a representative HIV "hotspot" with extremely high HIV prevalence (44.3%) and incidence (\~3.9/100py), yet low HIV service utilization. Hotspots such as Kasensero may seed and sustain HIV in general populations, compromising national and regional HIV control efforts. PEPFAR, UNAIDS, and WHO have recognized the urgent need to target hotspots with enhanced HIV treatment and prevention efforts. However, evidence on low-cost, comprehensive, and effective HIV control strategies for hotspots is limited and is thus a priority need for the field.

The investigators propose an implementation science, cluster-randomized, controlled trial in Kasensero to evaluate the impact on HIV service uptake and HIV incidence of CHWs promoting combination HIV prevention (CHP) services supported by mobile health technologies (mHealth). CHP is the implementation of multiple, evidence-based HIV prevention services (HIV testing and counseling, antiretroviral therapy, medical male circumcision, and behavior change) to maximize population-level impact on HIV incidence. For CHP to substantively decrease HIV incidence, most community members must be assessed for risk factors and current CHP utilization, then triaged, motivated, linked, and, if HIV-infected, retained in care. The proposed intervention will use low-cost CHWs leveraging mHealth decision support and counseling tools to promote CHP along this entire continuum of HIV service utilization. The hypotheses for this implementation science research are that residents in clusters receiving the implementation intervention will have improved CHP service uptake and decreased Population Prevalence of Viremia (PPDV) compared to controls receiving standard of care.

The intervention will be evaluated through a pragmatic, cluster-randomized trial nested within a large, ongoing population-based cohort study of HIV, the Rakai Community Cohort Study (RCCS). Intervention arm participants will be visited in their place of residence by CHWs trained to evaluate and triage participants into risk categories, provide tailored CHP health counseling, linkage, and adherence support, all supported by a mHealth decision support tool. The primary outcomes will be CHP service coverage and PPDV. Other outcomes will be HIV incidence, population viral load, implementation measures, retention, virologic suppression, and sexual behaviors.

Complimentary mixed methods (quantitative, qualitative, and cost) evaluations of the trial will be conducted to evaluate implementation processes, facilitators, and barriers to inform study results and future program uptake. Focus groups and in-depth interviews will be conducted during and after the follow-up period and synthesized with quantitative data. Intervention costs will be prospectively measured to provide information on program affordability.

Through this study, a novel, low-cost, and scalable implementation intervention to improve CHP uptake will be evaluated in an HIV "hotspot" critical to controlling the HIV epidemic. The study design ensures rigorous evidence of immediate relevance to many stakeholders.

02

Conditions studied

  • HIV
03

In context

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.

Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Resident of Kasensero

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
3,773 participants (actual)

Study arms

  • Experimental
    HealthScouts Intervention

    HealthScouts (CHWs) regularly visit residents and counsel them using a motivational interviewing approach, supported by a smartphone application.

    Behavioral: HealthScouts · Other: Standard of Care

  • Active comparator
    Standard of Care

    Referral by RCCS to HIV services. Free HIV clinic available in the community.

    Other: Standard of Care

Interventions

  • BehavioralHealthScouts
  • OtherStandard of Care
06

What researchers measure

Primary outcomes

  1. Population Prevalence of Detectable Viremia

    Proportion of the entire population who have detectable HIV viremia

    Time frame: 4 Years

  2. ART Coverage (self-report)

    Proportion of HIV+ persons who are on ART

    Time frame: 4 Years

  3. HIV Care Coverage (self-report)

    Proportion of HIV+ persons who are in HIV care

    Time frame: 4 years

  4. Medical Male Circumcision Coverage (self-report)

    Proportion of men who are circumcised

    Time frame: 4 years.

Secondary outcomes

  1. HIV Incidence

    Time frame: 4 years.

  2. Sexual Behaviors (self-report)

    Proportion of the population which has multiple partners and/or inconsistent or no condom use

    Time frame: 4 years

  3. Population HIV Viral Load

    The mean viral load of HIV+ persons

    Time frame: 4 years

  4. HIV Counseling and Testing Coverage (self-report)

    Proportion of the entire population who have received HIV Counseling and Testing

    Time frame: 4 years

  5. HIV Prevalence

    The prevalence of HIV in the entire population

    Time frame: 4 years

07

Study locations

1 site
  • Rakai Health Sciences Program
    Entebee, Uganda
08

References and documents

Publications

  • Chang LW, Mbabali I, Hutton H, Amico KR, Kong X, Mulamba J, Anok A, Ssekasanvu J, Long A, Thomas AG, Thomas K, Bugos E, Pollard R, van Wickle K, Kennedy CE, Nalugoda F, Serwadda D, Bollinger RC, Quinn TC, Reynolds SJ, Gray RH, Wawer MJ, Nakigozi G. Novel community health worker strategy for HIV service engagement in a hyperendemic community in Rakai, Uganda: A pragmatic, cluster-randomized trial. PLoS Med. 2021 Jan 6;18(1):e1003475. doi: 10.1371/journal.pmed.1003475. eCollection 2021 Jan. PubMed 33406130 ↗
  • Chang LW, Mbabali I, Kong X, Hutton H, Amico KR, Kennedy CE, Nalugoda F, Serwadda D, Bollinger RC, Quinn TC, Reynolds SJ, Gray R, Wawer M, Nakigozi G. Impact of a community health worker HIV treatment and prevention intervention in an HIV hotspot fishing community in Rakai, Uganda (mLAKE): study protocol for a randomized controlled trial. Trials. 2017 Oct 23;18(1):494. doi: 10.1186/s13063-017-2243-6. PubMed 29061194 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02556957
Lead sponsor
Johns Hopkins University
Responsible party
Sponsor
First posted
Sep 22, 2015
Start date
Sep 2015
Primary completion
Dec 2018
Completion
Dec 2018
Last update
Aug 31, 2020

Study contacts

Larry W Chang
principal investigator · Johns Hopkins School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion